Table 5 GRADE profile of collagen peptide supplementation for cardiovasscular risk factors scores in adults
Quality assessment | Summary of findings | Quality of evidence | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Outcomes | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication Bias | Participants (n) | WMD (95%CI) | Heterogeneity (I2) | ||
Camelina | Placebo | |||||||||
FBG | No serious limitations | Very serious Limitations | Serious Limitations | Serious Limitations | No serious limitations | 118 | 113 | −1.86 (−6.77, 3.06) | 89.0% | ⊕◯◯◯ Very low |
FI | No serious limitations | Very serious Limitations | Serious Limitations | Serious Limitations | No serious limitations | 118 | 113 | −0.10 (−0.72, 0.52) | 81.1% | ⊕◯◯◯ Very low |
LDL-C | No serious limitations | No serious limitations | No serious limitations | Serious Limitations | No serious limitations | 155 | 156 | −4.06 (−9.46, 1.34) | 3.1% | ⊕ ⊕ ⊕◯ Moderate |
HDL-C | No serious limitations | No serious Limitations | No serious limitations | Serious limitations | No serious limitations | 109 | 111 | −4.92 (−19.59, 9.76) | 31.5% | ⊕ ⊕ ⊕◯ Moderate |
TC | No serious limitations | No serious Limitations | No serious limitations | Serious Limitations | No serious limitations | 155 | 156 | −3.16 (−7.40, 1.09) | 0.0% | ⊕ ⊕ ⊕◯ Moderate |
TG | No serious limitations | No serious Limitations | No serious limitations | Serious Limitations | No serious limitations | 109 | 111 | 0.41 (−2.27, 3.12) | 0.0% | ⊕ ⊕ ⊕◯ Moderate |